Chemical Compound Review:
Tolvaptan N-[4-[(10-chloro-2-hydroxy- 6...
Synonyms:
Samsca, CHEMBL344159, SureCN242421, ANW-59865, OPC-41061, ...
Gheorghiade,
Gattis,
O'Connor,
Adams,
Elkayam,
Barbagelata,
Ghali,
Benza,
McGrew,
Klapholz,
Ouyang,
Orlandi,
Gheorghiade,
Gottlieb,
Udelson,
Konstam,
Czerwiec,
Ouyang,
Orlandi,
Munger,
Doggrell,
Miyazaki,
Yamamura,
Onogawa,
Nakamura,
Kinoshita,
Nakayama,
Fujiki,
Mori,
Konstam,
Gheorghiade,
Burnett,
Grinfeld,
Maggioni,
Swedberg,
Udelson,
Zannad,
Cook,
Ouyang,
Zimmer,
Orlandi,
Gheorghiade,
Niazi,
Ouyang,
Czerwiec,
Kambayashi,
Zampino,
Orlandi,
Gheorghiade,
Konstam,
Burnett,
Grinfeld,
Maggioni,
Swedberg,
Udelson,
Zannad,
Cook,
Ouyang,
Zimmer,
Orlandi,
Shoaf,
Elizari,
Wang,
Sekar,
Grinfeld,
Barbagelata,
Lerman,
Bramer,
Trongé,
Orlandi,
Costello-Boerrigter,
Smith,
Boerrigter,
Ouyang,
Zimmer,
Orlandi,
Burnett,
- Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. Wang, X., Gattone, V., Harris, P.C., Torres, V.E. J. Am. Soc. Nephrol. (2005)
- Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Miyazaki, T., Yamamura, Y., Onogawa, T., Nakamura, S., Kinoshita, S., Nakayama, S., Fujiki, H., Mori, T. Endocrinology (2005)
- Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Gheorghiade, M., Orlandi, C., Burnett, J.C., Demets, D., Grinfeld, L., Maggioni, A., Swedberg, K., Udelson, J.E., Zannad, F., Zimmer, C., Konstam, M.A. J. Card. Fail. (2005)
- Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia. Payvar, S., Orlandi, C., Stough, W.G., Elkayam, U., Ouyang, J., Casscells, S.W., Gheorghiade, M. Am. J. Cardiol. (2006)
- Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. Gheorghiade, M., Konstam, M.A., Burnett, J.C., Grinfeld, L., Maggioni, A.P., Swedberg, K., Udelson, J.E., Zannad, F., Cook, T., Ouyang, J., Zimmer, C., Orlandi, C. JAMA (2007)
- Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Cárdenas, A., Ginès, P., Marotta, P., Czerwiec, F., Oyuang, J., Guevara, M., Afdhal, N.H. J. Hepatology (2011)
- Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Costello-Boerrigter, L.C., Smith, W.B., Boerrigter, G., Ouyang, J., Zimmer, C.A., Orlandi, C., Burnett, J.C. Am. J. Physiol. Renal Physiol. (2006)
- OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. Yamamura, Y., Nakamura, S., Itoh, S., Hirano, T., Onogawa, T., Yamashita, T., Yamada, Y., Tsujimae, K., Aoyama, M., Kotosai, K., Ogawa, H., Yamashita, H., Kondo, K., Tominaga, M., Tsujimoto, G., Mori, T. J. Pharmacol. Exp. Ther. (1998)
- Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Gheorghiade, M., Gottlieb, S.S., Udelson, J.E., Konstam, M.A., Czerwiec, F., Ouyang, J., Orlandi, C. Am. J. Cardiol. (2006)
- Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Rangasetty, U.C., Gheorghiade, M., Uretsky, B.F., Orlandi, C., Barbagelata, A. Expert opinion on investigational drugs. (2006)
- Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. Gheorghiade, M., Gattis, W.A., O'Connor, C.M., Adams, K.F., Elkayam, U., Barbagelata, A., Ghali, J.K., Benza, R.L., McGrew, F.A., Klapholz, M., Ouyang, J., Orlandi, C. JAMA (2004)
- Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Goldsmith, S.R. Am. J. Cardiol. (2005)
- New agents for managing hyponatremia in hospitalized patients. Munger, M.A. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2007)
- Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. Shoaf, S.E., Elizari, M.V., Wang, Z., Sekar, K., Grinfeld, L.R., Barbagelata, N.A., Lerman, J., Bramer, S.L., Trongé, J., Orlandi, C. J. Cardiovasc. Pharmacol. Ther. (2005)
- Tolvaptan (Otsuka). Doggrell, S.A. Current opinion in investigational drugs (London, England : 2000) (2004)
- Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. Konstam, M.A., Gheorghiade, M., Burnett, J.C., Grinfeld, L., Maggioni, A.P., Swedberg, K., Udelson, J.E., Zannad, F., Cook, T., Ouyang, J., Zimmer, C., Orlandi, C. JAMA (2007)
- Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Gheorghiade, M., Niazi, I., Ouyang, J., Czerwiec, F., Kambayashi, J., Zampino, M., Orlandi, C. Circulation (2003)